San Diego-dependent Viking Therapeutics marked itself as a serious competitor while in the weight loss drug current market in February immediately after revealing promising information from the mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when provided as being a weekly injection